Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INJECTABL-II: IP-001 with Ablation for Colorectal Liver Metastases
NCT06630624Phase 2Recruiting
- Sponsor
- M.R. Meijerink
- Start
- Jul 2024
- Primary completion
- Aug 2029
- Modality
- Injectable Hydrogels, Implantable Hydrogels, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of IP-001 in colorectal cancer (CRC) (4 arms), sponsored by M.R. Meijerink. Primary endpoints: Maximum Tolerated Dose at 10 days, Distant Progression Free Survival at 1 year and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
IP-001
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06630624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630624.